These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 28322076)
1. Closer than ever to an Ebola virus vaccine. Banadyga L; Marzi A Expert Rev Vaccines; 2017 May; 16(5):401-402. PubMed ID: 28322076 [No Abstract] [Full Text] [Related]
2. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706 [TBL] [Abstract][Full Text] [Related]
3. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Tully CM; Lambe T; Gilbert SC; Hill AV Lancet Infect Dis; 2015 Mar; 15(3):356-9. PubMed ID: 25595637 [TBL] [Abstract][Full Text] [Related]
4. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA; Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510 [TBL] [Abstract][Full Text] [Related]
8. Ebola: Lessons on Vaccine Development. Feldmann H; Feldmann F; Marzi A Annu Rev Microbiol; 2018 Sep; 72():423-446. PubMed ID: 30200851 [TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. Mwesigwa B; Houser KV; Hofstetter AR; Ortega-Villa AM; Naluyima P; Kiweewa F; Nakabuye I; Yamshchikov GV; Andrews C; O'Callahan M; Strom L; Schech S; Anne Eller L; Sondergaard EL; Scott PT; Amare MF; Modjarrad K; Wamala A; Tindikahwa A; Musingye E; Nanyondo J; Gaudinski MR; Gordon IJ; Holman LA; Saunders JG; Costner PJM; Mendoza FH; Happe M; Morgan P; Plummer SH; Hickman SP; Vazquez S; Murray T; Cordon J; Dulan CNM; Hunegnaw R; Basappa M; Padilla M; Gajjala SR; Swanson PA; Lin BC; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Kibuuka H; Ake JA; Ledgerwood JE; Lancet Infect Dis; 2023 Dec; 23(12):1408-1417. PubMed ID: 37544326 [TBL] [Abstract][Full Text] [Related]
10. Ebola vaccines - Where are we? Watle SV; Norheim G; Røttingen JA Hum Vaccin Immunother; 2016 Oct; 12(10):2700-2703. PubMed ID: 27548643 [TBL] [Abstract][Full Text] [Related]
11. [Recent Advances in Vaccines and Drugs Against the Ebola Virus]. Zhu X; Yao C; Wei Y; Kou Z; Hu K Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536 [TBL] [Abstract][Full Text] [Related]